Pharma bro Martin Shkreli, who was arrested for securities fraud, is facing a new additional indictment charge. Shkreli made headlines last year when he chose to skyrocket prices for Daraprim, a treatment for cancer and AIDS patients, by 5,000. While the full details of the new charges have not been laid out, Shkreli is currently facing charges of fraud for transferring funds and lying to investors about his finances, while claiming to have assets under management that did not exist. Shkreli was also involved in fake consulting agreements to settle claims with investors from earlier failed hedge funds. Joya Mia Italiano and Nik Zecevic take a closer look at the latest indictment against Shkreli on the Lip News.